NCT00506298已完成2 期
A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin.
Zalicus1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2007年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90
研究概览
简要总结
This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking metformin to treat their diabetes. In addition, this initial trial will evaluate insulin resistance (HOMA-IR index), HgbA1c levels, glycated protein, LDL, HDL, triglycerides, and total cholesterol, as well as the safety of CRx-401.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must voluntarily give written informed consent
- •Must be between 18-75 years of age
- •Must have Type 2 diabetes for ≥ 6 months
- •HgbA1C between 7.0% and 9.5%
- •FPG > 6.7 mmol/L (120 mg/dL)
- •BMI: Lower limit of 27 kg/m2 and an upper Limit of 45 kg/m2
- •Treatment with a stable dosage for ≥ 8 weeks of either Glucophage metformin) ≥ 1000 and ≤ 2500 mg/day OR Glucophage XR ≤ 2000 mg/day
- •eGFR ≥ 70 mL/min
排除标准
- •History of any clinically significant atherosclerotic disorder including myocardial infarction (within 6 months of screening), angina, stroke, peripheral vascular disease or congestive heart failure
- •Known hypersensitivity or idiosyncratic reaction related to fibrates or NSAIDs including photo-allergic or phototoxic reactions to fibrates
- •Subjects in whom acute asthmatic attacks, urticaria, or rhinitis are precipitated by aspirin or other NSAIDs
- •History of clinically significant (as determined by the investigator cardiac, hematologic, hepatobiliary, peptic ulcer, renal, immunologic, metabolic, urologic, pulmonary, endocrinologic, neurologic, dermatologic, psychiatric, and/or other major disease
- •Type 1 Diabetes
- •Evidence of Cushing's syndrome, untreated hypothyroidism or other disorders that may lead to secondary weight gain, insulin resistance, or Type 2 diabetes
- •Proliferative diabetic retinopathy or significant neuropathic symptoms that also limit activities of daily living
- •History of malignancy (except for treated or excised basal cell carcinoma)
- •Surgery within the 90 days prior to screening except for minor dental or cosmetic procedures
- •History of drug or alcohol abuse (as defined by the Investigator)
- •History of opportunistic infection
- •Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to screening
- •Fever or symptomatic viral or bacterial infection within 2 weeks prior to screening
- •Positive for HCV antibody
- •Positive for HBsAg
- •Known positive for HIV antibody
- •Pharmacologic treatment with statins, unless dosage has been stable ≥ three months and is unlikely to change over the course of the study.
- •Treatment with any concomitant medication that has not been at a stable dose for at least 28 days prior to screening.
- •Currently taking or planning to take during the trial:
- •Sulphonylureas, Injected hypoglycemic (exanatide or insulin), Weight loss medications, Thiazolidenediones, Glucocorticoids (inhaled glucocorticoids are permitted), Digoxin, Anticoagulants, Phenytoin, Loratadine, Erythromycin, MAO-inhibitors, NSAIDs (ASA ≤ 81 mg/d is permitted), COX-2 Inhibitors, Cholestryramine or fibrates, DPP-IV inhibitors, Any herbal medications unless reviewed with study doctor
- •Alanine aminotransferase ALT) or aspartate aminotransferase (AST laboratory values that exceed > 2.0 x upper limit of normal (ULN)
- •White blood cell (WBC) count < 4.0 x 109 /L or >14.0 X 109 /L
- •Hemoglobin < 105 g/L in females and < 110 g/L in males (< 10.5 g/dL in females and < 11.0 g/dL in males)
- •Participation in another clinical trial and/or treatment received with any investigational agent within 30 days before the initial dose of study medication
- •Female subject who is pregnant or lactating or of child bearing potential and not using acceptable methods of contraception (birth control pills, barriers or abstinence)
- •Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule
- •Other unspecified reasons that, in the opinion of the Investigator or sponsor make the subject unsuitable for enrollment
研究组 & 干预措施
A
Experimental
CRx-401 (bezafibrate + diflunisal)
干预措施: bezafibrate + diflunisal (Drug)
B
Active Comparator
bezafibrate + placebo
干预措施: bezafibrate + placebo (Drug)
结局指标
主要结局
The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90
时间窗: Day 90
次要结局
- The exploratory efficacy endpoints will measure change in the following parameters: HOMA Index, HgbA1C, fructosamine, LDL, HDL, OGTT, triglycerides and total cholesterol from Baseline to Day 90(Day 90)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Metformin in Patients With Fragile XFragile X SyndromeNCT04141163Rowan University40
已完成
2 期
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 DiabetesType 2 DiabetesNCT00871936Response Pharmaceuticals82
Unknown
2 期
Glaser Obesity StudyObesityNCT00209482Glaser Pediatric Research Network76
已完成
1 期
Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT02949700Baylor College of Medicine26
已完成
2 期
Combination of Metformin With Gefitinib to Treat NSCLCEGFR Gene AmplificationAdvanced CancerStage IIIB NSCLCStage IV NSCLCNSCLCNCT01864681Daping Hospital and the Research Institute of Surgery of the Third Military Medical University224